Amarin Corp Plc (AMRN)

[north40000]

NASH and NAFLD are multi-billion markets. There are currently no FDA approved medications to treat those indications. GILD has been looking a long time for a medication that would satisfy that unmet need.

Does Vascepa have sufficient potency in suppression of inflammation to warrant GILD to think seriously about a license, collaboration, or buyout activity with Amarin? Needless to say, such potential would be enormous when added to the CVD activity shown by Reduce-It.

There is substantial “competition” from other entities; the potential is summarized by either a market- watch or Benzinga article last January 2019. I read the article last evening; it is located in my IRA TDA website under GILD news.